{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:43:38Z","timestamp":1788965018338,"version":"build-2803163510"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Anti-synthetase syndrome (ASS) is a rare autoimmune myopathy, frequently associated with interstitial lung disease, and is characterized by the presence of anti-aminoacyl tRNA synthetase (ARS) antibodies. However, there have been limited reports of cases exhibiting positive anti-Ha antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study presents a retrospective analysis of the clinical data from a patient with an acute exacerbation of ASS who tested positive for anti-Ha antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>This patient initially presented with interstitial pneumonia. The initial anti-infective treatment was ineffective; however, symptoms improved following the addition of corticosteroids. Upon discontinuation of corticosteroids, the patient experienced a recurrence of cough, progressive worsening of dyspnea, and developed lower general weakness. Comprehensive autoantibody testing revealed positivity for anti-Ha antibodies, and MRI of the lower limbs indicated soft tissue edema. The patient was ultimately diagnosed with ASS with interstitial lung disease. Treatment with methylprednisolone pulse therapy, combined with cyclophosphamide, tacrolimus, tofacitinib citrate, and pirfenidone, led to an improvement in the patient\u2019s condition, resulting in discharge. Post-discharge, the patient was maintained on regular oral prednisone, nintedanib, and tofacitinib. Follow-up to date has shown a stable condition, with resolution of pulmonary lesions observed upon re-examination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Anti-Ha antibody is one of the specific antibodies associated with ASS, yet its positive rate remains exceedingly low. This case represents the first reported instance of an anti-Ha antibody-positive ASS in China. Misdiagnosis and missed diagnosis are prevalent in clinical practice, underscoring the importance of screening for autoantibodies when patients present with acute, unexplained interstitial lung changes and a poor response to anti-infective treatment. Furthermore, interstitial lung disease is the most common extra-muscular clinical manifestation observed in ASS patients. Differentiating between acute exacerbations of pulmonary infections and interstitial lung disease associated with rheumatic diseases poses a significant challenge, as both can occur concurrently. Therefore, during diagnosis and treatment, it is crucial to consider not only infections but also to identify the underlying causes of worsening lung lesions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1614777","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T04:10:53Z","timestamp":1749701453000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Acute exacerbation of anti-Ha antibody-positive antisynthetase syndrome-associated interstitial lung disease: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Yinying","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiya","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxi","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanlan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minchao","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.rmed.2016.07.009","article-title":"Clinical fea-tures and outcomes of interstitial lung disease in anti-Jo-1 posi-tive antisynthetase syndrome","volume":"118","author":"Zamora","year":"2016","journal-title":"Respir Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2014.11.026","article-title":"Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings","volume":"84","author":"Debray","year":"2015","journal-title":"Eur J Radiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/20018525.2019.1583516","article-title":"Clinical characteristics and outcome in patients with antisynthetase syndrome associated interstitial lung disease: a retrospective cohort study","volume":"6","author":"Jensen","year":"2019","journal-title":"Eur Clin Respir J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.916178","article-title":"Antisynthetase syndrome and autoantibodies: a literature review and report of 4 cases","volume":"20","author":"Marin","year":"2019","journal-title":"Am J Case Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2016.11.021","article-title":"Antisynthetase syndrome: analysis of 11 cases","volume":"148","author":"Zamarr\u00f3n\u2043de Lucas","year":"2017","journal-title":"Med Clin"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0366-6999.2010.05.002","article-title":"Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study","volume":"123","author":"Ji","year":"2010","journal-title":"Chin Med J(Engl)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/B0R00000000000548","article-title":"New insights in myositis- peiffi au-toantibodies","volume":"30","author":"Ghirardello","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.022","article-title":"Idiopathic iffammatory myopathies and the anti-synthetase syndrome: a comprehensive review","volume":"13","author":"Mahler","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutualexclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn141217-20230215-00041","article-title":"A case of anti-synthetase syndrome with positive anti-Zo antibody","volume":"27","author":"Guo","year":"2023","journal-title":"Chin J Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.3390\/jcm9092944","article-title":"Prevalence of novel myositis autoantibodies in a large cohort of patients with interstitial lung disease","volume":"9","author":"Moll","year":"2020","journal-title":"J Clin Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez504","article-title":"The myositis clinical phenotype associated with anti-Zo autoantibodies:A case series of nine UK patients","volume":"59","author":"Tansley","year":"2019","journal-title":"Rheumatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.3390\/jcm8112013","article-title":"Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course","volume":"8","author":"Cavagna","year":"2019","journal-title":"J Clin Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41584-021-00721-z","article-title":"Acute exacerbation of interstitial lung disease associated with rheumatic disease","volume":"18","author":"Luppi","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq073","article-title":"Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.872615","article-title":"Clinical features, prognostic factors, and survival of patients with antisynthetase syndrome and interstitial lung disease","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"B18","article-title":"Clinical experience withpirfenidoneinfivepatientswithscleroderma-relatedinterstitial lung disease","volume":"31","author":"Miura","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, phase IIstudy of the safety and tolerability of pirfenidone in patientswith scleroderma -associated interstitial lung disease: theLOTUSS trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"33226","DOI":"10.1038\/srep33226","article-title":"Pirfenidone in patients with rapidlyprogressive interstitial lung disease assocated with cinicallyamyopathic dermatomyositis","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rrp"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0578-1426.2018.08.005","article-title":"2018 Chinese expert-based consensus statement regarding the diagnosis and treatment of interstitial lung disease associated with connective tissue diseases","volume":"57","year":"2018","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies:what progress has been made in the past 35 years","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"}],"updated-by":[{"DOI":"10.3389\/fimmu.2025.1647113","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1614777\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T06:45:52Z","timestamp":1750920352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1614777\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2025.1614777"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1614777","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fimmu.2025.1647113","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"article-number":"1614777"}}